Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model

doi:10.3390/cancers11121889

Review

. 2019 Nov 27;11(12):1889.

doi: 10.3390/cancers11121889.

Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model

Carla De Giovanni¹, Giordano Nicoletti², Lorena Landuzzi², Arianna Palladini¹, Pier-Luigi Lollini¹, Patrizia Nanni¹

Affiliations

¹ Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum University of Bologna, Bologna I-40126, Italy.
² Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna I-40136, Italy.

PMID: 31783695
PMCID: PMC6966465
DOI: 10.3390/cancers11121889

Review

Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model

Carla De Giovanni et al. Cancers (Basel). 2019.

. 2019 Nov 27;11(12):1889.

doi: 10.3390/cancers11121889.

Authors

Carla De Giovanni¹, Giordano Nicoletti², Lorena Landuzzi², Arianna Palladini¹, Pier-Luigi Lollini¹, Patrizia Nanni¹

Affiliations

¹ Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum University of Bologna, Bologna I-40126, Italy.
² Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna I-40136, Italy.

PMID: 31783695
PMCID: PMC6966465
DOI: 10.3390/cancers11121889

Abstract

The TS/A cell line was established in 1983 from a spontaneous mammary tumor arisen in an inbred BALB/c female mouse. Its features (heterogeneity, low immunogenicity and metastatic ability) rendered the TS/A cell line suitable as a preclinical model for studies on tumor-host interactions and for gene therapy approaches. The integrated biological profile of TS/A resulting from the review of the literature could be a path towards the description of a precision experimental model of mammary cancer.

Keywords: TS/A; gene therapy; immunotherapy; metastases; murine mammary cancer; preclinical models.

PubMed Disclaimer

Conflict of interest statement

The University of Bologna granted to EMD Millipore license for TS/A distribution worldwide. Royalties are destined for oncological research.

Figures

**Figure 1**
Origin of the TS/A cell line and variants. For pictures see [51].

**Figure 2**
Morphology of the TS/A cell line in adherent culture (phase contrast, ×100).

See this image and copyright information in PMC

Cited by

Targeting hepcidin in colorectal cancer triggers a TNF-dependent-gasdermin E-driven immunogenic cell death response.
Di Grazia A, Franzè E, Frascatani R, Laudisi F, Pacifico T, Tomassini L, Di Fusco D, Formica V, Sica G, Stolfi C, Monteleone I, Monteleone G. Di Grazia A, et al. Exp Hematol Oncol. 2024 Sep 27;13(1):95. doi: 10.1186/s40164-024-00562-y. Exp Hematol Oncol. 2024. PMID: 39334507 Free PMC article.
Targeting the Oxytocin Receptor for Breast Cancer Management: A Niche for Peptide Tracers.
Kalaba P, Sanchez de la Rosa C, Möller A, Alewood PF, Muttenthaler M. Kalaba P, et al. J Med Chem. 2024 Feb 8;67(3):1625-1640. doi: 10.1021/acs.jmedchem.3c01089. Epub 2024 Jan 18. J Med Chem. 2024. PMID: 38235665 Free PMC article. Review.
Evaluating [¹⁸F]FDG and [¹⁸F]FLT Radiotracers as Biomarkers of Response for Combined Therapy Outcome in Triple-Negative and Estrogen-Receptor-Positive Breast Cancer Models.
Rainone P, Valtorta S, Villa C, Todde S, Cadamuro M, Bertoli G, Conconi D, Lavitrano M, Moresco RM. Rainone P, et al. Int J Mol Sci. 2023 Sep 15;24(18):14124. doi: 10.3390/ijms241814124. Int J Mol Sci. 2023. PMID: 37762429 Free PMC article.
Tumor Radiosensitization by Gene Electrotransfer-Mediated Double Targeting of Tumor Vasculature.
Savarin M, Znidar K, Sersa G, Komel T, Cemazar M, Kamensek U. Savarin M, et al. Int J Mol Sci. 2023 Feb 1;24(3):2755. doi: 10.3390/ijms24032755. Int J Mol Sci. 2023. PMID: 36769077 Free PMC article.
Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape.
Hicks KC, Chariou PL, Ozawa Y, Minnar CM, Knudson KM, Meyer TJ, Bian J, Cam M, Schlom J, Gameiro SR. Hicks KC, et al. Nat Commun. 2021 Aug 26;12(1):5151. doi: 10.1038/s41467-021-25393-x. Nat Commun. 2021. PMID: 34446712 Free PMC article.

See all "Cited by" articles

References

1. Letai A. Functional precision cancer medicine-moving beyond pure genomics. Nat. Med. 2017;23:1028–1035. doi: 10.1038/nm.4389. - DOI - PubMed
1. Gould S.E., Junttila M.R., De Sauvage F.J. Translational value of mouse models in oncology drug development. Nat. Med. 2015;21:431–439. doi: 10.1038/nm.3853. - DOI - PubMed
1. Heppner G.H., Miller F.R., Shekhar P.V.M. Nontransgenic models of breast cancer. Breast Cancer Res. 2000;2:331–334. doi: 10.1186/bcr77. - DOI - PMC - PubMed
1. Gengenbacher N., Singhal M., Augustin H.G. Preclinical mouse solid tumour models: Status quo, challenges and perspectives. Nat. Rev. Cancer. 2017;17:751–765. doi: 10.1038/nrc.2017.92. - DOI - PubMed
1. Haynes B., Sarma A., Nangia-Makker P., Shekhar M.P. Breast cancer complexity: Implications of intratumoral heterogeneity in clinical management. Cancer Metastasis Rev. 2017;36:547–555. doi: 10.1007/s10555-017-9684-y. - DOI - PMC - PubMed

Publication types

Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Research Materials
- Cellosaurus - a cell line knowledge resource
- NCI CPTC Antibody Characterization Program

[1] Letai A. Functional precision cancer medicine-moving beyond pure genomics. Nat. Med. 2017;23:1028–1035. doi: 10.1038/nm.4389. - DOI - PubMed

[2] Letai A. Functional precision cancer medicine-moving beyond pure genomics. Nat. Med. 2017;23:1028–1035. doi: 10.1038/nm.4389. - DOI - PubMed

[3] Gould S.E., Junttila M.R., De Sauvage F.J. Translational value of mouse models in oncology drug development. Nat. Med. 2015;21:431–439. doi: 10.1038/nm.3853. - DOI - PubMed

[4] Gould S.E., Junttila M.R., De Sauvage F.J. Translational value of mouse models in oncology drug development. Nat. Med. 2015;21:431–439. doi: 10.1038/nm.3853. - DOI - PubMed

[5] Heppner G.H., Miller F.R., Shekhar P.V.M. Nontransgenic models of breast cancer. Breast Cancer Res. 2000;2:331–334. doi: 10.1186/bcr77. - DOI - PMC - PubMed

[6] Heppner G.H., Miller F.R., Shekhar P.V.M. Nontransgenic models of breast cancer. Breast Cancer Res. 2000;2:331–334. doi: 10.1186/bcr77. - DOI - PMC - PubMed

[7] Gengenbacher N., Singhal M., Augustin H.G. Preclinical mouse solid tumour models: Status quo, challenges and perspectives. Nat. Rev. Cancer. 2017;17:751–765. doi: 10.1038/nrc.2017.92. - DOI - PubMed

[8] Gengenbacher N., Singhal M., Augustin H.G. Preclinical mouse solid tumour models: Status quo, challenges and perspectives. Nat. Rev. Cancer. 2017;17:751–765. doi: 10.1038/nrc.2017.92. - DOI - PubMed

[9] Haynes B., Sarma A., Nangia-Makker P., Shekhar M.P. Breast cancer complexity: Implications of intratumoral heterogeneity in clinical management. Cancer Metastasis Rev. 2017;36:547–555. doi: 10.1007/s10555-017-9684-y. - DOI - PMC - PubMed

[10] Haynes B., Sarma A., Nangia-Makker P., Shekhar M.P. Breast cancer complexity: Implications of intratumoral heterogeneity in clinical management. Cancer Metastasis Rev. 2017;36:547–555. doi: 10.1007/s10555-017-9684-y. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model

Affiliations

Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

Grants and funding

LinkOut - more resources

Full Text Sources

Research Materials